exRNAdisease

Entry Detail

---



General Information

Database ID: exR0087615 RNA Name: hsa-miR-1181 RNA Type: miRNA Chromosome: chr19 Starnd: - Coordinate: Start Site(bp): 10403505 End Site(bp): 10403525 External Links: hsa-miR-1181

Disease Information

Disease Name: Breast Cancer Disease Category: Cancers MeSH ID: D001943 Type: Neoplasms/Breast Neoplasms Alias: Breast Neoplasms//Breast Neoplasm//Neoplasm, Breast//Breast Tumors//Breast Tumor//Tumor, Breast//Tumors, Breast//Neoplasms, Breast//Breast Cancer//Cancer, Breast//Mammary Cancer//Cancer, Mammary//Cancers, Mammary//Mammary Cancers//Malignant Neoplasm of Breast//Breast Malignant Neoplasm//Breast Malignant Neoplasms//Malignant Tumor of Breast//Breast Malignant Tumor//Breast Malignant Tumors//Cancer of Breast//Cancer of the Breast//Mammary Carcinoma, Human//Carcinoma, Human Mammary//Carcinomas, Human Mammary//Human Mammary Carcinomas//Mammary Carcinomas, Human//Human Mammary Carcinoma//Mammary Neoplasms, Human//Human Mammary Neoplasm//Human Mammary Neoplasms//Neoplasm, Human Mammary//Neoplasms, Human Mammary//Mammary Neoplasm, Human//Breast Carcinoma//Breast Carcinomas//Carcinoma, Breast//Carcinomas, Breast

Expression Detail

GEO ID: GSE101841 Description: Serum microRNA profile of Her2 positive metastatic breast cancer patients Experimental Design: Trastuzumab therapy Case Disease Type: Breast Cancer Case Disease SubType: HER2 positive metastatic breast cancer Case Sample: Breast Cancer Trastuzumab resistant Control Sample: Trastuzumab sensitive Number of Case: 42 Number of Control: 61 Number of Samples: 103

Regulatory Relationship

mRNA targets: Gene Symbol Chromosome Start Site(bp) End Site(bp) Strand CDC37 chr19 10391133 10420121 - CHD7 chr8 60678740 60868028 + IRS2 chr13 109752695 109786583 - MAZ chr16 29806106 29811164 + PIM1 chr6 37170152 37175428 + RRP1B chr21 43659560 43696079 + ZMIZ1 chr10 79068966 79316528 + CAMK4 chr5 111223653 111494886 + ELF1 chr13 40931924 41061440 - GNAS chr20 58839718 58911192 + GSPT1 chr16 11868128 11916082 - HNRNPA0 chr5 137745651 137754363 - HNRNPUL2 chr11 62712630 62727457 - HNRNPUL2-BSCL2 chr11 62690275 62727384 - IMMT chr2 86143932 86195770 - MDFIC chr7 114922154 115019202 + PRKAA2 chr1 56645314 56715335 + RAB21 chr12 71754863 71800286 + RALY chr20 33993646 34108308 + SLC4A4 chr4 71062667 71572087 + SOX1 chr13 112067149 112071706 + SPINT2 chr19 38244035 38292615 + TMEFF1 chr9 100473149 100577636 + TTC3 chr21 37073226 37203112 + U2AF1 chr21 43092956 43107587 - U2AF1L5 chr21 6484623 6499261 - UBE2D2 chr5 139526431 139628434 + ZNF282 chr7 149195546 149226238 + miRNA targets: NA circRNA targets: NA lncRNA targets: lncRNA Symbol Chromosome Start Site(bp) End Site(bp) Strand AC007216.1 chr16 11976851 11977850 - Display:

Experiment Detail

GEO ID: GSE101841 Sample Source: Blood Source Fraction: Serum Platform: GPL23138 Method: Microarray Num of detected RNA Type: 1 Num of detected RNAs of this Type: 1808 Sample treatment protocol: NA RNA Extract protocol: Total RNA was extracted from 103 samples with the Plasma RNA Purification Mini Kit (51000, NorgenBiotek Corporation, Canada), following manufacturer's instructions. RNA library preparation protocol: Total RNA extracted from 600ul serum was employed with 100 nmol/L of pCp-DY647 and 15 Units of T4 RNA ligase in a total reaction volume of 20 ul at 16°C overnight.

Reference

PMID: 29691399 Title: A serum microRNA signature predicts trastuzumab benefit in HER2-positive metastatic breast cancer patients. Author: Li H, Liu J, Chen J, Wang H, Yang L, Chen F, Fan S, Wang J, Shao B, Yin D, Zeng M, Li M, Li J, Su F, Liu Q, Yao H, Su S, Song E Journal: Nat Commun. 2018 Apr 24;9(1):1614. Description: MicroRNAs (miRNAs) have been used to predict therapeutic effects for various cancers, but whether miRNAs can serve as biomarkers for HER2+ metastatic breast cancer (MBC) patients remains unclear.